EGFR and non-small cell lung carcinoma: In all, osimertinib, although effective, is not economically friendly for patients with EGFR‐mutated patients with advanced NSCLC, but decreasing its price might make it more favorable in cost‐effectiveness, especially for patients with T790M mutations.